logo logo

Vytorin drug review

The U.S. Food and Drug Administration (FDA) have released results after a year long review of the drug Vytorin.

The FDA said patients should not stop taking Vytorin or other cholesterol lowering drugs, based on its review of a previous controversial study of Vytorin.


The reason for the review

On January 25, 2008 the FDA announced that it would be reviewing data from the ENHANCE trial of the drug Vytorin. Early results had shown there was no evidence that Vytorin drug controlled plaque buildup in arteries any more than Zocor alone.

Vytorin is a more expensive combination drug of Zocor (Simvastatin) and Zetia (Ezetimibe).


Results from the review

The FDA released a statement on the 8th of January, 2009 after a years review of Vytorin.

They found the difference in the changes in carotid artery thickness between those taking Zocor and those taking Vyttorin was not statistically significant. However they found, LDL “bad” cholesterol decreased by 56% in the Vytorin group and decreased by 39% in the simvastatin group.


The FDA position

The FDA states that high LDL cholesterol is a risk factor for cardiovascular disease. Drugs that reduce bad cholesterol benefit patients at risk of heart attack, stroke, or sudden death.

Patients should not stop taking Vytorin or other cholesterol lowering medications and should talk to their doctor if they have any questions or concerns.


Related articles

bottom


bottom KellieMyHS

About Kellie

Kellie is 37 years old and together with her brother Steve makes up the My Health Software team.

She helps on the websites and gathering news for the programs. Kellie worked in the medical industry prior to having her two children (8 and 6) and has a strong interest in self awareness and management of health conditions.


bottom

News "home delivered"

Note: These news headlines are now automatically displayed on the home page of the My Health Software applications for Windows.

The news is updated regularly, and you can click through to these items to read more.


bottom